The Survival and Ventricular Enlargement (SAVE) study was designed to
test the hypothesis that chronic use of the angiotensin-converting enz
yme (ACE) inhibitor captopril in survivors of myocardial infarction wi
th left ventricular dysfunction would prevent a further deterioration
of ventricular function and thereby improve clinical outcome. The stud
y did demonstrate that randomization to the ACE inhibitor resulted in
improved survival and, specifically, lessened cardiovascular deaths. T
he prestudy rationale that less ventricular enlargement would be obser
ved in ACE inhibitor treated patients was validated by an echocardiogr
aphic substudy. As anticipated, fewer patients treated with the ACE in
hibitor went on to manifest the prespecified definitions of more overt
congestive heart failure. Importantly, not only were the manifestatio
ns of congestive heart failure reduced, there were fewer fatal events
subsequent to development of failure. Although this concept of attenua
tion of progressive remodeling leading to benefits was upheld, the stu
dy also yielded other observations to support the generation of new hy
potheses to explain a component of the overall benefit of ACE inhibito
r therapy. Particularly attractive, and supported by observations from
the Studies of Left Ventricular Dysfunction (SOLVD) studies, is the r
eduction in myocardial infarction and subsequent death following myoca
rdial infarction with chronic ACE inhibitor therapy. These clinical ob
servations point to an important potentially modifiable interface betw
een the renin-angiotensin system and the risk of experiencing a corona
ry atherosclerotic event. Although the value of ACE inhibition therapy
in patients with acute and chronic myocardial infarction is already c
linically apparent, new mechanistic hypotheses generating information
have provided further stimulus for basic and clinical research which w
ill undoubtedly lead to an even greater understanding of the pathophys
iology of myocardial infarction.